Modulators of telomerase activity

Effect of atorvastatin therapy and perindopril therapy on telomerase activity in patients free of cardiovascular diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN55050065

Enrollment

152

Registered

2016-02-16

Start date

2013-04-05

Completion date

Unknown

Last updated

2016-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Hypercholesterolemia 2. Hypertension Nutritional, Metabolic, Endocrine 1. Hypercholesterolemia 2. Hypertension

Interventions

Part one - Atorvastatin arm: Participants are randomized (using of a table of random numbers) to one of two groups in a 1:1 ratio. Intervention group: Participants receive 20mg atorvastatin daily fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All participants: Aged 35 to 75 years Atorvastatin arm: 1. Diagnosed with hypercholesterolemia (low-density lipoproteins cholesterol [LDL-C] =160 mg/dL (4.16 mmol/L) in the presence of 0–1 CVD risk factors and LDL-C =130 mg/dL (3.38 mmol/L) in the presence of two or more CVD risk factors 2. Absence of any lipid-lowering therapy at the time of inclusion Perindopril arm: 1. Hypertension grade 1-2

Exclusion criteria

Exclusion criteria: 1. Any chronic somatic diseases, including CVD associated with atherosclerosis, grade 3 hypertension, chronic heart failure (NYHA III–IV), chronic kidney disease (glomerular filtration rate <60 mL/min/1.73m2), liver disease, type 2 diabetes mellitus, acute and chronic inflammatory diseases, cancer, pregnancy, lactation 2. Refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Telomerase activity, measured by quantitative polymerase chain reaction at 12 months	—

Secondary

Measure	Time frame
1. Markers of chronic inflammation (C-reactive protein, fibrinogen, interleukin 6), measured using blood analysis at baseline and 12 months 2. Blood urea, measured using uranalysis at baseline and 12 months 3. Carotid-femoral pulse wave velocity, measured using SphygmoCor at baseline and 12 months 4. Intima-media thickness and atherosclerotic plaques number, measured using ultrasonography with PHILIPS iU22 ultrasound system at baseline and 12 months 5. Flow dependent vasodilation, measured by probe with reactive hyperemia at baseline and 12 months	—

Measure

Time frame

1. Markers of chronic inflammation (C-reactive protein, fibrinogen, interleukin 6), measured using blood analysis at baseline and 12 months 2. Blood urea, measured using uranalysis at baseline and 12 months 3. Carotid-femoral pulse wave velocity, measured using SphygmoCor at baseline and 12 months 4. Intima-media thickness and atherosclerotic plaques number, measured using ultrasonography with PHILIPS iU22 ultrasound system at baseline and 12 months 5. Flow dependent vasodilation, measured by probe with reactive hyperemia at baseline and 12 months

—

Countries

Russian Federation

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 1, 2026